{"id":11060,"date":"2020-12-14T12:08:00","date_gmt":"2020-12-14T16:08:00","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11060"},"modified":"2026-10-28T14:35:27","modified_gmt":"2026-10-28T18:35:27","slug":"numi-gains-54-percent-nia-members-up-696-percent","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/technicals\/numi-gains-54-percent-nia-members-up-696-percent\/","title":{"rendered":"NUMI Gains 54% to $2.27, NIA Members Up 696%"},"content":{"rendered":"\n

On Saturday, December 5th, <\/span>NIA issued an important<\/span><\/strong> Numinus Wellness (TSXV: NUMI) alert<\/span><\/b> at <\/span>$0.78 per share<\/strong> in which we <\/span>explained the significance<\/strong><\/span> of <\/span>NUMI's collaboration<\/span><\/strong> with <\/span>MAPS<\/strong> for a <\/span>compassionate access trial<\/strong><\/span> in <\/span>Canada<\/strong> of <\/span>MDMA-assisted psychotherapy<\/strong> for the <\/span>treatment<\/span><\/strong> of <\/span>PTSD<\/strong><\/span>. Amazingly, the <\/span>news<\/strong> initially got <\/span>almost no reaction<\/strong><\/span> when it was <\/span>released<\/strong><\/span> on December 2nd, because of the fact that <\/span>MAPS<\/strong> is a <\/span>non-profit<\/span> organization <\/strong>that the <\/span>average bandwagon<\/span> investor<\/span><\/strong> in the <\/span>psychedelic space<\/strong><\/span> <\/span>never even heard<\/strong><\/span> of prior to the announcement.<\/span><\/p>\n\n

After NIA sent out the news<\/span><\/strong> on Saturday, December 5th and explained<\/strong><\/span> its significance<\/span><\/strong>, NUMI gained by 88.46%<\/span><\/strong> last week to close Friday at $1.47 per share<\/strong>. NUMI gained 9X more<\/span><\/strong> last week than it did during the prior week when NUMI's MAPS news <\/strong>was first published<\/strong><\/span>. This past weekend, the news began to spread<\/span><\/strong> among the rest of the investment community<\/strong>. NUMI <\/strong>has rallied another 54.42%<\/span><\/strong> this morning to hit a new all-time high<\/strong><\/span> of $2.27 per share<\/b> for a gain of 696.49%<\/strong><\/span> since NIA's September 27th<\/strong> suggestion<\/strong><\/span> of NUMI<\/strong> as its #1 favorite psychedelic stock suggestion<\/strong><\/span> and one of NIA's Top 5 favorite overall stock suggestions<\/span><\/strong> at $0.285 per share<\/strong>. NUMI's U.S. OTC<\/strong> symbol LKYSF<\/strong> traded record<\/span> volume<\/strong> on Monday, September 28th, the first trading day following NIA's initial<\/span> NUMI announcement<\/span><\/strong>.<\/span><\/span><\/p>\n\n

NIA expects MAPS <\/strong>to receive<\/span> FDA approval<\/span><\/strong> of MDMA-assisted psychotherapy<\/strong> for the treatment<\/span><\/strong> of PTSD<\/b><\/span> as early as 2022<\/strong> with MDMA-assisted psychotherapy <\/strong>likely to become available<\/span> <\/strong>for PTSD sufferers<\/span> (victims<\/span> <\/strong>of the military industrial complex <\/strong>and its endless wars<\/span>) <\/strong>as early as 2023<\/strong>. We expect MAPS<\/strong> to receive<\/span> FDA approval<\/span><\/strong> of MDMA-assisted psychotherapy prior to<\/span> Compass Pathways (CMPS) receiving<\/span> FDA approval<\/span> <\/strong>of psilocybin-assisted psychotherapy <\/strong>for treatment-resistant depression<\/span><\/strong>.<\/span><\/span><\/p>\n\n

As MAPS Founder Dr. Rick Doblin<\/strong> explained<\/strong><\/span> to NIA's President Gerard Adams <\/strong>last year, "We're basically gonna have six years of being the monopoly seller<\/span> of MDMA. There's 10 million people<\/span> in the U.S. that have PTSD<\/span>. We're talking about an incredible need<\/span> for the product."<\/strong><\/em><\/span><\/span><\/p>\n\n

Besides NUMI's <\/strong>proposed compassionate access trial<\/strong><\/span> in Canada<\/strong> in collaboration<\/strong><\/span> with MAPS<\/strong> of MDMA-assisted psychotherapy<\/strong> for the treatment<\/span><\/strong> of PTSD<\/strong><\/span>, the most significant<\/span><\/strong> psychedelic clinical trial<\/strong> of a small-cap publicly traded<\/span> company<\/strong> in North America is Revive Therapeutics (CSE: RVV)'s <\/strong>proposed "Phase I Study of the Safety<\/span> and Feasibility<\/span> of Psilocybin in Adults with Methamphetamine Use Disorder<\/span>."<\/strong><\/span><\/span><\/p>\n\n

RVV <\/strong>has already proven its ability<\/span> <\/strong>to take a drug <\/strong>called Bucillamine into<\/span> Phase III FDA clinical trials <\/strong>and they have a strong<\/span> clinical trial partner<\/span> <\/strong>the University of Wisconsin School of Medicine and Public Health <\/strong>that RVV <\/strong>has already signed<\/strong><\/span> a Clinical Trial Agreement<\/strong> with! RVV's clinical trial partner<\/span><\/strong> is already conducting a similar study<\/strong><\/span> of psilocybin<\/strong> as a treatment<\/strong><\/span> for Opioid Use Disorder<\/span><\/strong>, but we believe RVV<\/strong> has made the best choice<\/strong><\/span> to focus on Methamphetamine Use Disorder <\/span><\/strong>because it has no<\/span> FDA <\/b>approved treatments<\/b><\/span>, but psilocybin<\/strong> is already showing tremendous promise<\/strong><\/span>!<\/span><\/span><\/p>\n\n

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from NUMI of USD$30,000 cash for a six-month marketing contract. NIA has received compensation from RVV of USD$30,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.<\/em><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

On Saturday, December 5th, NIA issued an important Numinus Wellness (TSXV: NUMI) alert at $0.78 per share in which we explained the significance of NUMI's collaboration with MAPS for a compassionate access trial in Canada of MDMA-assisted psychotherapy for the treatment of PTSD. Amazingly, the news initially got almost no reaction when it was released […]<\/p>\n","protected":false},"author":1,"featured_media":11061,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[365,307,310,311],"class_list":["post-11060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technicals","tag-biotech","tag-cmps","tag-numi","tag-rvv"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11060"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11060\/revisions"}],"predecessor-version":[{"id":11062,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11060\/revisions\/11062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11061"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}